CDK inhibitors suppress Th17 and promote iTreg differentiation, and ameliorate experimental autoimmune encephalomyelitis in mice

Biochemical and Biophysical Research Communications

Volumn 435, Issue 3, 2013, Pages 378-384

  Yoshida, Hideyuki ^a,b   Kotani, Hitoshi ^a,b   Kondo, Taisuke ^a,b   Tani, Ito ^a,b   Wei, Xuetao ^a,b,c   Tsuruta, Sanae ^a,b   Kimura, Akihiro ^a,b   Asakawa, Mayako ^a,b   Ito, Minako ^a,b   Nagai, Shigenori ^a,b   Yoshimura, Akihiko ^a,b  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

CDK; Cytokine signaling; Helper T cells; Th17

Indexed keywords

1 [N,O BIS(5 ISOQUINOLINESULFONYL) N METHYLTYROSYL] 4 PHENYLPIPERAZINE; 4 [4 (1,3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL]BENZAMIDE; 4 AMINO 7 TERT BUTYL 5 (4 METHYLPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; ACLARUBICIN; BREFELDIN A; CHECKPOINT KINASE 2 INHIBITOR; CHIR 99021; CYCLIN DEPENDENT KINASE INHIBITOR; D 4476; DEXAMETHASONE; INTERLEUKIN 2; KENPAULLONE; PROTEIN KINASE INHIBITOR; PROTEIN KINASE R INHIBITOR; PROTEIN SERINE THREONINE KINASE INHIBITOR; PURVALANOL A; RETINOID RELATED ORPHAN RECEPTOR GAMMA; ROSCOVITINE; STAT5 PROTEIN; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG SCREENING; IMMUNOMODULATION; LYMPHOCYTE DIFFERENTIATION; MEDIATOR; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TH17 CELL;

ANIMALS; BENZAZEPINES; CELL DIFFERENTIATION; CYCLIN-DEPENDENT KINASES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; INDOLES; MICE; MICE, INBRED C57BL; PROTEIN KINASE INHIBITORS; T-LYMPHOCYTES, REGULATORY; TH17 CELLS;

MUS;

EID: 84878974454     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.04.096     Document Type: Article

References (37)

1. Mosmann T.R., Coffman R.L. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 1989, 7:145-173.
2. Yoshimura A., Wakabayashi Y., Mori T. Cellular and molecular basis for the regulation of inflammation by TGF-beta. J. Biochem. 2010, 147:781-792.
3. Bettelli E., Carrier Y., Gao W., Korn T., Strom T.B., Oukka M., Weiner H.L., Kuchroo V.K. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441:235-238.
4. Mangan P.R., Harrington L.E., O'Quinn D.B., Helms W.S., Bullard D.C., Elson C.O., Hatton R.D., Wahl S.M., Schoeb T.R., Weaver C.T. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 2006, 441:231-234.
5. Veldhoen M., Hocking R.J., Atkins C.J., Locksley R.M., Stockinger B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006, 24:179-189.
6. Ivanov B.S., McKenzie L., Zhou C.E., Tadokoro A., Lepelley J.J., Lafaille D.J., Cua D.R. Littman, The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 2006, 126:1121-1133.
7. Yang X.O., Pappu B.P., Nurieva R., Akimzhanov A., Kang H.S., Chung Y., Ma L., Shah B., Panopoulos A.D., Schluns K.S., Watowich S.S., Tian Q., Jetten A.M., Dong C. T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma. Immunity 2008, 28:29-39.
8. Ichiyama K., Yoshida H., Wakabayashi Y., Chinen T., Saeki K., Nakaya M., Takaesu G., Hori S., Yoshimura A., Kobayashi T. Foxp3 inhibits RORgammat-mediated IL-17A mRNA transcription through direct interaction with RORgammat. J. Biol. Chem. 2008, 283:17003-17008.
9. Zhou L., Lopes J.E., Chong M.M., Ivanov, Min R., Victora G.D., Shen Y., Du J., Rubtsov Y.P., Rudensky A.Y., Ziegler S.F., Littman D.R. TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function. Nature 2008, 453:236-240.
10. Ichiyama K., Hashimoto M., Sekiya T., Nakagawa R., Wakabayashi Y., Sugiyama Y., Komai K., Saba I., Moroy T., Yoshimura A. Gfi1 negatively regulates T(h)17 differentiation by inhibiting RORgammat activity. Int. Immunol. 2009, 21:881-889.
11. Zhu J., Davidson T.S., Wei G., Jankovic D., Cui K., Schones D.E., Guo L., Zhao K., Shevach E.M., Paul W.E. Down-regulation of Gfi-1 expression by TGF-beta is important for differentiation of Th17 and CD103+ inducible regulatory T cells. J. Exp. Med. 2009, 206:329-341.
12. Takimoto T., Wakabayashi Y., Sekiya T., Inoue N., Morita R., Ichiyama K., Takahashi R., Asakawa M., Muto G., Mori T., Hasegawa E., Saika S., Hara T., Nomura M., Yoshimura A. Smad2 and Smad3 are redundantly essential for the TGF-beta-mediated regulation of regulatory T plasticity and Th1 development. J. Immunol. 2010, 185:842-855.
13. Biswas P.S., Gupta S., Chang E., Song L., Stirzaker R.A., Liao J.K., Bhagat G., Pernis A.B. Phosphorylation of IRF4 by ROCK2 regulates IL-17 and IL-21 production and the development of autoimmunity in mice. J. Clin. Invest. 2010, 120:3280-3295.
14. Kawada M., Inoue H., Masuda T., Ikeda D. Insulin-like growth factor I secreted from prostate stromal cells mediates tumor-stromal cell interactions of prostate cancer. Cancer Res. 2006, 66:4419-4425.
15. Sekiya T., Kashiwagi I., Yoshida R., Fukaya T., Morita R., Kimura A., Ichinose H., Metzger D., Chambon P., Yoshimura A. Nr4a receptors are essential for thymic regulatory T cell development and immune homeostasis. Nature Immunol. 2013, 14:230-237.
16. H. Yoshida, A. Kimura, T. Fukaya, T. Sekiya, R. Morita, T. Shichita, H. Inoue, A. Yoshimura, Low dose CP-690,550 (tofacitinib), a pan-JAK inhibitor, accelerates the onset of experimental autoimmune encephalomyelitis by potentiating Th17 differentiation, Biochem. Biophys. Res. Commun. (2012).
17. Takahashi R., Nishimoto S., Muto G., Sekiya T., Tamiya T., Kimura A., Morita R., Asakawa M., Chinen T., Yoshimura A. SOCS1 is essential for regulatory T cell functions by preventing loss of Foxp3 expression as well as IFN-{gamma} and IL-17A production. J. Exp. Med. 2011, 208:2055-2067.
18. Hasegawa E., Sonoda K.H., Shichita T., Morita R., Sekiya T., Kimura A., Oshima Y., Takeda A., Yoshimura T., Yoshida S., Ishibashi T., Yoshimura A. IL-23-Independent Induction of IL-17 from gammadeltaT Cells and Innate Lymphoid Cells Promotes Experimental Intraocular Neovascularization. J. Immunol. 2013, 190:1778-1787.
19. Koga K., Takaesu G., Yoshida R., Nakaya M., Kobayashi T., Kinjyo I., Yoshimura A. Cyclic adenosine monophosphate suppresses the transcription of proinflammatory cytokines via the phosphorylated c-Fos protein. Immunity 2009, 30:372-383.
20. Saeki K., Fukuyama S., Ayada T., Nakaya M., Aki D., Takaesu G., Hanada T., Matsumura Y., Kobayashi T., Nakagawa R., Yoshimura A. A major lipid raft protein raftlin modulates T cell receptor signaling and enhances th17-mediated autoimmune responses. J. Immunol. 2009, 182:5929-5937.
21. Ichiyama K., Sekiya T., Inoue N., Tamiya T., Kashiwagi I., Kimura A., Morita R., Muto G., Shichita T., Takahashi R., Yoshimura A. Transcription factor Smad-independent T helper 17 cell induction by transforming-growth factor-beta is mediated by suppression of eomesodermin. Immunity 2011, 34:741-754.
22. Bain J., McLauchlan H., Elliott M., Cohen P. The specificities of protein kinase inhibitors: an update. Biochem. J. 2003, 371:199-204.
23. Leclerc S., Garnier M., Hoessel R., Marko D., Bibb J.A., Snyder G.L., Greengard P., Biernat J., Wu Y.Z., Mandelkow E.M., Eisenbrand G., Meijer L. Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?. J. Biol. Chem. 2001, 276:251-260.
24. Kunick C., Schultz C., Lemcke T., Zaharevitz D.W., Gussio R., Jalluri R.K., Sausville E.A., Leost M., Meijer L. 2-Substituted paullones: CDK1/cyclin B-inhibiting property and in vitro antiproliferative activity. Bioorganic Med. Chem. Lett. 2000, 10:567-569.
25. Meijer L., Borgne A., Mulner O., Chong J.P., Blow J.J., Inagaki N., Inagaki M., Delcros J.G., Moulinoux J.P. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. European J. Biochem./FEBS 1997, 243:527-536.
26. Hajduch M., Havlieek L., Vesely J., Novotny R., Mihal V., Strnad M. Synthetic cyclin dependent kinase inhibitors. New generation of potent anti-cancer drugs. Adv. Experim. Med. Biol. 1999, 457:341-353.
27. A. Laurence, C.M. Tato, T.S. Davidson, Y. Kanno, Z. Chen, Z. Yao, R.B. Blank, F. Meylan, R. Siegel, L. Hennighausen, E.M. Shevach, J. O'Shea J, Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation, Immunity 26 (2007) 371-381.
28. 3+ regulatory T cells. J. Immunol. 2007, 178:280-290.
29. Wakabayashi Y., Tamiya T., Takada I., Fukaya T., Sugiyama Y., Inoue N., Kimura A., Morita R., Kashiwagi I., Takimoto T., Nomura M., Yoshimura A. Histone 3 lysine 9 (H3K9) methyltransferase recruitment to the interleukin-2 (IL-2) promoter is a mechanism of suppression of IL-2 transcription by the transforming growth factor-beta-Smad pathway. J. Biol. chem. 2011, 286:35456-35465.
30. Taniguchi K., Kohsaka H., Inoue N., Terada Y., Ito H., Hirokawa K., Miyasaka N. Induction of the p16INK4a senescence gene as a new therapeutic strategy for the treatment of rheumatoid arthritis. Nature Med. 1999, 5:760-767.
31. Nasu K., Kohsaka H., Nonomura Y., Terada Y., Ito H., Hirokawa K., Miyasaka N. Adenoviral transfer of cyclin-dependent kinase inhibitor genes suppresses collagen-induced arthritis in mice. J. Immunol. 2000, 165:7246-7252.
32. Sekine C., Sugihara T., Miyake S., Hirai H., Yoshida M., Miyasaka N., Kohsaka H. Successful treatment of animal models of rheumatoid arthritis with small-molecule cyclin-dependent kinase inhibitors. J. Immunol. 2008, 180:1954-1961.
33. Nonomura Y., Nagasaka K., Hagiyama H., Sekine C., Nanki T., Tamamori-Adachi M., Miyasaka N., Kohsaka H. Direct modulation of rheumatoid inflammatory mediator expression in retinoblastoma protein-dependent and -independent pathways by cyclin-dependent kinase 4/6. Arthritis Rheumatism 2006, 54:2074-2083.
34. Murakami Y., Mizoguchi F., Saito T., Miyasaka N., Kohsaka H. P16(INK4a) exerts an anti-inflammatory effect through accelerated IRAK1 degradation in macrophages. J. Immunol. 2012, 189:5066-5072.
35. Chunder N., Wang L., Chen C., Hancock W.W., Wells A.D. Cyclin-dependent kinase 2 controls peripheral immune tolerance. J. Immunol. 2012, 189:5659-5666.
36. Liu F. Smad3 phosphorylation by cyclin-dependent kinases. Cytokine Growth Factor Rev. 2006, 17:9-17.
37. Baughn L.B., Di Liberto M., Niesvizky R., Cho H.J., Jayabalan D., Lane J., Liu F., Chen-Kiang S. CDK2 phosphorylation of Smad2 disrupts TGF-beta transcriptional regulation in resistant primary bone marrow myeloma cells. J. Immunol. 2009, 182:1810-1817.